业绩预期 - Vertex Pharmaceuticals (VRTX) 预计季度每股收益为 $4.08，同比增长 8.5% [1] - 分析师预测营收为 $25亿，同比增长 8.5% [1] - 分析师对本季度的每股收益预期在过去30天内上调了0.4% [2] - 分析师集体评估显示，Trikafta/Kaftrio 产品的收入预计将达到 $23亿，同比增长 +13.6% [6] - 分析师集体评估显示，Kalydeco 产品的收入预计将达到 $1.0745 亿，同比下降 -21% [7] - 分析师预计 Orkambi 产品的收入将达到 $7781 万，同比下降 -29.9% [8] - 分析师预计 Symdeko 产品的收入将达到 $2573 万，同比下降 -24.3% [9] 盈利预期 - 研究表明，盈利预期修订趋势与股票短期价格表现之间存在强烈相关性 [3] - 投资者通常依赖于共识盈利和营收预期来评估季度业绩，但深入分析分析师对某些关键指标的预测往往能提供更全面的理解 [4]

Good news from the lab sparked a mini-rally in Vertex Pharmaceuticals (VRTX 2.35%) stock on Tuesday. The biotech's shares closed the trading session more than 2% higher in price, which was good enough to top the flat-lining S&P 500 index. One of the company's investigational drugs is showing decent promise in a clinical trial. Pain drug meets primary endpoint in study Vertex announced that its VX-548, a non-opioid medication aimed at treating moderate to severe acute pain, met its primary endpoint in a phas ...

A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston on Oct. 23, 2019. Vertex Pharmaceuticals on Tuesday said its experimental painkiller, which is being tested as an alternative to addictive opioids, significantly decreased post-surgery pain in late-stage trials The drug, known as VX-548, did not work better than a popular opioid, however. Still, the trial results bring the biotech company one step closer to developing a drug that can provide strong pain relief without the ad ...

VX-548临床试验结果 - Vertex Pharmaceuticals宣布了针对选择性NaV1.8抑制剂VX-548在中度至重度急性疼痛治疗中的第三阶段试验取得了积极结果[1] - VX-548在腹部整形术或拇外翻术后的治疗中显示出显著改善疼痛强度差异的主要终点，以及48小时时与安慰剂相比的疼痛减轻[2] - VX-548在两项关键次要终点中显示出更快的有效疼痛缓解时间，且在安全性和耐受性方面表现良好[3] - VX-548的安全性和有效性研究结果显示了其在广泛的急性疼痛条件下的潜力，为填补耐受性良好但疗效有限的药物和存在成瘾风险的阿片类药物之间的差距提供了理想的位置[4]

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $435.82, with a +1.31% movement compared to the previous day. This change outpaced the S&P 500's 0.76% gain on the day. Elsewhere, the Dow gained 0.59%, while the tech-heavy Nasdaq added 1.12%. Shares of the drugmaker have appreciated by 5.72% over the course of the past month, outperforming the Medical sector's gain of 1.57% and the S&P 500's gain of 2.5%. The upcoming earnings release of Vertex Pharmaceuticals will be of great interest to i ...

Vertex制药公司 - Vertex制药公司在囊性纤维化（CF）领域拥有垄断地位，预计2023年全年收入将达到100亿美元，净利润约为36亿美元[3] - Vertex即将推出一种新的三联疗法，可能比公司已获批的CF产品效果更好，且每日一次的用药更为方便[5] - Vertex与Moderna合作开发mRNA疗法，有望帮助5000多名无法从CFTR调节剂中受益的CF患者[6]

Those who put money in Vertex Pharmaceuticals (VRTX 0.57%) 10 years ago are sitting pretty right now. The company has easily outpaced the market over this period. However, a lot has changed for the biotech in the meantime, and as we all know, past success isn't a guarantee of anything. Can Vertex pull off another market-beating performance through the next decade? Let's dig into what's going on with the biotech and determine where it might be in 10 years. VAL ANN ® Vertex Pharmaceuticals Inc (VRTX) Total Re ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Vertex Pharmaceuticals (VRTX) . Vertex currently has an average ...

股价表现 - Vertex Pharmaceuticals (VRTX) 最近收盘价为 $439.70，较前一个交易日下跌了 0.09% [1] - Vertex Pharmaceuticals 的股价在过去一个月内上涨了 8.6%，超过了医疗行业的 2.29% 和标普500指数的 2.08% [2] 财务预测 - 分析师预计 Vertex Pharmaceuticals 将在 2024年2月5日发布财报，预计每股收益为 $4.08，同比增长 8.51%，预计营收为 $25亿，同比增长 8.52% [3] 分析师评级 - Vertex Pharmaceuticals 目前的 Zacks Rank 为 2 (买入)，过去一个月 Zacks Consensus EPS 估计上调了 0.15% [6] 估值比较 - Vertex Pharmaceuticals 目前的 Forward P/E 比率为 26.57，高于行业平均值 23.69 [7] - Vertex Pharmaceuticals 目前的 PEG 比率为 2.59，高于医疗 - 生物医学和遗传学行业的平均值 1.88 [8] 行业排名 - 医疗 - 生物医学和遗传学行业的 Zacks Industry Rank 为 96，位于所有 250+ 行业的前 39% [9] - Zacks Industry Rank 衡量了行业群体的强度，研究显示排名前 50% 的行业胜过后 50% 的行业 2 倍 [10]

股价表现 - Vertex Pharmaceuticals (VRTX) 最近的股价为 $433.76，较前一天收盘价下跌了 -0.85%。[1] - 过去一个月，这家药企的股价上涨了8.52%，表现优于医疗行业的3.8%和标普500指数的1.2%。[2] 财报预测 - 预计 Vertex Pharmaceuticals 即将公布的每股收益为 $4.08，较去年同期增长了8.51%。[3] - 最新的市场共识预测公司营收为 25亿美元，较去年同期增长了8.52%。[3] 分析师预测 - 投资者应关注 Vertex Pharmaceuticals 的分析师预测是否有最新变化，修订传达了分析师对公司业绩和利润潜力的信心。[4] Zacks Rank 系统 - Zacks Rank 系统从 1（强热门）到 5（强卖出）的范围内，具有出色的绩效记录，目前 Vertex Pharmaceuticals 的 Zacks Rank 为 2（买入）。[6] 估值指标 - Vertex Pharmaceuticals 目前的前瞻市盈率为26.45，相对于行业平均前瞻市盈率 22.08，该公司的估值处于溢价状态。[7] - VRTX 目前的 PEG 比率为2.58，高于医疗 - 生物医学和遗传学行业的平均 PEG 比率1.84。[8] 行业排名 - 医疗 - 生物医学和遗传学行业属于医疗行业，目前的 Zacks 行业排名为74，位于所有250+行业的前30%。[9] 行业实力 - Zacks 行业排名显示，排名前50%的行业表现优于后50%的行业，比例为2比1。[10] 未来展望 - 要关注 Vertex Pharmaceuticals 在未来交易日的表现，请务必使用 Zacks.com。[11]